



## Supplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016

January 31, 2017  
NITTO DENKO CORPORATION

### CONTENTS

	Page
◆ Business Results	1
◆ Segment Information	2
◆ Segment Information By Geographic Area	4
<u>Revenue to customers outside Japan</u>	

(Note) In the amounts of money in this material, fractions below the shown figures are omitted.  
Percentages(%) are rounded to the nearest decimal point.

Forward-looking statements such as those relating to earnings forecasts and other projections contained in this material are management's current assumptions and beliefs based on currently available information. Such forward-looking statements are subject to a number of risks, uncertainties and other factors. Accordingly, actual results may differ materially from those projected due to various factors.

# Business Results

(Unit: Billions of yen ( ): % of change from the same period of previous year)

		Revenue	Operating	Net Income
FY2015 Apr.-Dec.	Results	<b>623.3</b>	<b>89.5</b>	<b>70.7</b>
FY2016 Apr.-Dec.	Results	<b>566.2</b> (-9.2)	<b>64.7</b> (-27.7)	<b>46.4</b> (-34.3)

(Unit: Billions of yen ( ): % of change from the previous year)

Forecasts of FY2016	As of Oct 31, 2016	<b>720.0</b> (-9.2)	<b>70.0</b> (-31.6)	<b>50.0</b> (-39.0)
	As of Jan 31, 2017	<b>760.0</b> (-4.2)	<b>85.0</b> (-17.0)	<b>61.0</b> (-25.6)

(Billions of yen)

		Depreciation expenses	Capital Investment	R&D Expenditures
FY2016 Apr.-Dec.	Results	<b>36.3</b>	<b>28.5</b>	<b>22.6</b>
Forecasts of FY2016	As of Oct 31, 2016	<b>50.0</b>	<b>50.0</b>	<b>32.0</b>
	As of Jan 31, 2017	<b>49.0</b>	<b>42.0</b>	<b>30.0</b>

(Yen/1US\$)

Exchange Rate	Q1	<b>111.1</b>	Q2	<b>106.9</b>	Q3	<b>106.4</b>	Q4	<b>115.0</b>
---------------	----	--------------	----	--------------	----	--------------	----	--------------

## Topics

### ◆ Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto

Bristol-Myers Squibb Company and Nitto have entered into an agreement granting Bristol-Myers Squibb exclusive worldwide rights for the development and commercialization of Nitto's investigational siRNA molecules targeting heat shock protein 47 (HSP47) in vitamin A containing formulations, which includes Nitto's lead asset ND-L02-s0201, for the treatment of advanced liver fibrosis. The agreement also grants Bristol-Myers Squibb the option to receive exclusive licenses for HSP47 siRNAs in vitamin A containing formulations for the treatment of lung fibrosis and other organ fibrosis.  
<http://www.nitto.com/jp/en/press/2016/1111.jsp>

### ◆ Nitto Named One of the 2016 Top 100 Global IP/Patents-related Innovators

Nitto has been selected as one of the "2016 Top 100 Global Innovators" for the 6th consecutive year by Clarivate Analytics, formerly the IP & Science unit of Thomson Reuters. Nitto has made a companywide effort to appropriately protect the ideas for our inventions with intellectual property rights while also maximizing the value of our ideas by effectively commercializing them. In recent years, with the global expansion of the company's business, we have actively promoted the globalization of our intellectual property initiatives, and we believe that these initiatives have led to our recognition with this award.  
<http://www.nitto.com/jp/en/press/2017/0111.jsp>

### ◆ Initiation of Phase I Clinical Trial for Seasonal Influenza HA Vaccine Sublingual Tablet

Nitto initiated phase I clinical trials to sublingually administer a seasonal influenza HA vaccine tablet (code: NSV0001), a joint development with the Research Foundation for Microbial Diseases of Osaka University on October 2016 in Japan. Nitto also aims for practical realization of this influenza vaccine as a first step and plans to expand this platform to other vaccines in the future.  
<http://www.nitto.com/jp/en/press/2016/1102.jsp>

# Segment Information

## Revenue & Operating Income by Segment

(Yen in millions)

		FY2015 Results			FY2016 Results				Forecasts		
		3Q (Oct.-Dec.)	Apr-Dec	FY2015	2Q (Jul.-Sep.)	3Q (Oct.-Dec.)		Apr.-Dec.		FY2016	
						Y-o-Y(%)	Y-o-Y(%)	Y-o-Y(%)	Y-o-Y(%)		
Industrial Tape	Functional base products	50,837	149,527	191,134	46,875	50,674	99.7	139,395	93.2	184,000	96.3
	Transportation	31,521	94,686	125,534	29,790	30,716	97.4	90,888	96.0	123,000	98.0
	Revenue	82,358	244,213	316,668	76,666	81,390	98.8	230,284	94.3	307,000	96.9
	Operating income	6,754	20,372	24,885	6,114	7,615	112.7	19,001	93.3	25,000	100.5
Optronics	Information fine materials	99,652	306,565	380,805	87,685	96,963	97.3	258,569	84.3	348,000	91.4
	Flexible printed circuits	14,285	41,914	51,533	10,386	11,619	81.3	31,725	75.7	43,000	83.4
	Processing materials	5,653	17,615	23,625	5,972	5,702	100.9	17,363	98.6	24,000	101.6
	Revenue	119,590	366,095	455,963	104,045	114,284	95.6	307,658	84.0	415,000	91.0
	Operating income	20,866	64,638	69,058	9,588	17,712	84.9	31,993	49.5	45,000	65.2
Life Science	Revenue	6,676	16,706	23,976	7,794	18,405	275.7	33,048	197.8	44,000	183.5
	Operating income	1,202	615	2,287	2,064	12,333	1,025.6	16,794	2,728.7	20,000	874.5
Others	Revenue	7,602	22,429	29,562	6,468	5,859	77.1	19,340	86.2	26,000	88.0
	Operating income	676	2,394	2,917	-79	-864	-	-799	-	-2,000	-
Elimination &Corporate	Revenue	-8,591	-26,071	-33,116	-8,408	-8,703	-	-24,116	-	-32,000	-
	Operating income	-71	1,567	3,249	-134	-1,306	-	-2,206	-	-3,000	-
Total	Revenue	207,636	623,373	793,054	186,566	211,236	101.7	566,215	90.8	760,000	95.8
	Operating income	29,427	89,588	102,397	17,552	35,490	120.6	64,783	72.3	85,000	83.0

(Note) Because of increased quantitative materiality of the medical business, partial changes have been made to reporting segments with change of management system. Such changes have also been reflected in the figures for FY2015.

- 1 Therapy and therapeutic drugs for fibrotic diseases have been added to "Medical" as "Life Science" since the third quarter ended December 31, 2016.
- 2 New businesses have been added to "Membrane" as "Others" since the third quarter ended December 31, 2016.

# Segment Information (Reference)

(Yen in millions)

		FY2015 Results			FY2016 Results					Forecasts	
		3Q (Oct.-Dec.)	Apr-Dec	FY2015	2Q (Jul.-Sep.)	3Q (Oct.-Dec.)		Apr.-Dec.		FY2016	
						Y-o-Y(%)	Y-o-Y(%)	Y-o-Y(%)	Y-o-Y(%)		
Medical & Membrane	Medical products	6,676	16,706	23,976	7,794	7,185	107.6	21,828	130.7	32,800	136.8
	Membrane products	7,582	22,314	29,391	6,462	5,857	77.3	19,272	86.4	25,900	88.1
	Revenue	14,258	39,021	53,368	14,257	13,043	91.5	41,101	105.3	58,700	110.0
	Operating income	3,372	7,504	11,285	4,015	1,785	52.9	10,068	134.2	14,500	128.5

(Note) Since the third quarter ended December 31, 2016, therapy and therapeutic drugs for fibrotic diseases have been added to "Medical" as "Life Science", and new businesses have been added to "Membrane" as "Others". The above is the results of "Medical & Membrane". There is no change with "Industrial Tape" and "Optronics".

## Segment Information by Geographic Area

(Yen in Millions)

		Japan	Americas	Europe	Asia & Oceania	Total	Eliminations & Corporate	Consolidated Total
		Apr.-Dec. FY2015	Revenue to outside customers	138,038	55,514	31,804	398,015	623,373
	Inter-segment revenue or transfers	289,145	6,606	3,525	26,200	325,477	-325,477	-
	<b>Total</b>	<b>427,183</b>	<b>62,120</b>	<b>35,330</b>	<b>424,216</b>	<b>948,851</b>	<b>-325,477</b>	<b>623,373</b>
	Operating Income	56,230	7,934	2,100	24,092	90,357	-769	89,588

		Japan	Americas	Europe	Asia & Oceania	Total	Eliminations & Corporate	Consolidated Total
		Apr.-Dec. FY2016	Revenue to outside customers	143,850	55,017	29,421	337,925	566,215
	Inter-segment revenue or transfers	249,688	6,681	3,012	25,173	284,556	-284,556	-
	<b>Total</b>	<b>393,539</b>	<b>61,699</b>	<b>32,434</b>	<b>363,099</b>	<b>850,772</b>	<b>-284,556</b>	<b>566,215</b>
	Operating Income	31,976	10,372	2,400	22,224	66,974	-2,190	64,783

Note: 1 Countries or regions are segmented by geographical proximity.

Note: 2 Major countries or regions excluding Japan represented by categories:

Americas : U.S.A., Mexico, Brazil

Europe : Belgium, France, Germany, Sweden, Turkey

Asia & Oceania : China, Korea, Taiwan, Singapore, Malaysia, Hong Kong, Thailand

## Revenue to customers outside Japan

(Yen in Millions)

		Americas	Europe	Asia & Oceania	Others	Total
		Apr.-Dec. FY2015	Revenue to customers outside Japan	48,475	35,927	364,647
	Consolidated revenue	/				623,373
	Ratio of revenue to customers outside Japan to consolidated revenue	7.8%	5.8%	58.5%	0.1%	72.2%

		Americas	Europe	Asia & Oceania	Others	Total
		Apr.-Dec. FY2016	Revenue to customers outside Japan	48,115	32,560	316,292
	Consolidated revenue	/				566,215
	Ratio of revenue to customers outside Japan to consolidated revenue	8.5%	5.8%	55.9%	0.2%	70.3%

Note: 1 Countries or regions are segmented by geographical proximity.

Note: 2 Major countries or regions excluding Japan represented by categories:

Americas : U.S.A., Mexico, Brazil

Europe : Belgium, France, Germany, Sweden, Turkey

Asia & Oceania : China, Korea, Taiwan, Singapore, Malaysia, Hong Kong, Thailand

Note: 3 Revenue to customers outside Japan represent the revenue by the parent company and its consolidated subsidiaries in the countries or regions outside Japan.